Literature DB >> 9098879

Covalent binding of a bucillamine derivative with albumin in sera from healthy subjects and patients with various diseases.

R Narazaki1, M Otagiri.   

Abstract

PURPOSE: To investigate the difference of pharmacokinetics of thiol-containing drugs in various disease states, we studies the covalent binding of SA3786, a bucillamine derivative, with proteins in patient serum compared with that in healthy serum.
METHODS: Sera from healthy volunteers and patients of various diseases were supplied by the Japanese Red Cross Kumamoto Hospital. For the formation of conjugate experiments, SA3786 was added to a final concentration of 7 x 10(-4)M. After 6 h incubation at 37 degrees C, HPLC analysis of 5 microliters aliquots of each sample was performed using a column of N-methylpyridinium polymer (4VP-Me).
RESULTS: The extent of HSA-SA3786 conjugate formation was found to be lower in the sera from healthy volunteers (control) than those from patients of various diseases. Especially high reactivity with SA3786 was observed in sera from rheumatic patients and hepatic patients. With the exception of the fraction of mercaptoalbumin (fHMA), none of the parameters showed a good correlation with conjugate formation.
CONCLUSIONS: The parameter fHMA must be considered to be one of the most important factors in formation of conjugates between plasma protein and thiol compounds. However, other factors may be involved in addition to fHMA although the nature of these factors is not clear.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9098879     DOI: 10.1023/a:1012006306915

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

Review 1.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

2.  THE MICROHETEROGENEITY OF PLASMA ALBUMINS. II. PREPARATION AND SOLUBILITY PROPERTIES OF SUBFRACTIONS.

Authors:  H A PETERSEN; J F FOSTER
Journal:  J Biol Chem       Date:  1965-06       Impact factor: 5.157

3.  On the sulfhydryl group of human plasma albumin.

Authors:  T P KING
Journal:  J Biol Chem       Date:  1961-02       Impact factor: 5.157

Review 4.  Drug-protein conjugation and its immunological consequences.

Authors:  B K Park; N R Kitteringham
Journal:  Drug Metab Rev       Date:  1990       Impact factor: 4.518

5.  Biotransformation of the disulfide of captopril in subcellular fractions of rat tissues.

Authors:  S J Lan; S H Weinstein; B H Migdalof
Journal:  Drug Metab Dispos       Date:  1982 Jul-Aug       Impact factor: 3.922

6.  Covalent binding between bucillamine derivatives and human serum albumin.

Authors:  R Narazaki; M Hamada; K Harada; M Otagiri
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

7.  D-penicillamine and D-penicillamine-protein disulphide in plasma and synovial fluid of patients with rheumatoid arthritis.

Authors:  D A Joyce; R O Day
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

8.  Increased oxidized form of human serum albumin in patients with diabetes mellitus.

Authors:  E Suzuki; K Yasuda; N Takeda; S Sakata; S Era; K Kuwata; M Sogami; K Miura
Journal:  Diabetes Res Clin Pract       Date:  1992-12       Impact factor: 5.602

9.  The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: comparison with patients with normal renal function.

Authors:  O H Drummer; B S Workman; P J Miach; B Jarrott; W J Louis
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Captopril kinetics in chronic congestive heart failure.

Authors:  R J Cody; G L Schaer; A B Covit; K Pondolfino; G Williams
Journal:  Clin Pharmacol Ther       Date:  1982-12       Impact factor: 6.875

View more
  3 in total

Review 1.  Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties.

Authors:  K Oettl; R E Stauber
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

2.  Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases.

Authors:  Kohei Nagumo; Motohiko Tanaka; Victor Tuan Giam Chuang; Hiroko Setoyama; Hiroshi Watanabe; Naoyuki Yamada; Kazuyuki Kubota; Motoko Tanaka; Kazutaka Matsushita; Akira Yoshida; Hideaki Jinnouchi; Makoto Anraku; Daisuke Kadowaki; Yu Ishima; Yutaka Sasaki; Masaki Otagiri; Toru Maruyama
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

Review 3.  The Interplay between Uremic Toxins and Albumin, Membrane Transporters and Drug Interaction.

Authors:  Regiane Stafim da Cunha; Carolina Amaral Bueno Azevedo; Carlos Alexandre Falconi; Fernanda Fogaça Ruiz; Sophie Liabeuf; Marcela Sorelli Carneiro-Ramos; Andréa Emilia Marques Stinghen
Journal:  Toxins (Basel)       Date:  2022-02-26       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.